US12612368B2 - Cancer treatments targeting cancer stem cells - Google Patents

Cancer treatments targeting cancer stem cells

Info

Publication number
US12612368B2
US12612368B2 US17/774,583 US202017774583A US12612368B2 US 12612368 B2 US12612368 B2 US 12612368B2 US 202017774583 A US202017774583 A US 202017774583A US 12612368 B2 US12612368 B2 US 12612368B2
Authority
US
United States
Prior art keywords
alkyl
certain embodiments
substituted
unsubstituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US17/774,583
Other languages
English (en)
Other versions
US20230023124A1 (en
Inventor
Yushma BHURRUTH-ALCOR
Gregory Thomas Crimmins
Dennise Alexandra De Jesús Diaz
Caroline Mae Robb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Remedy Plan Inc
Original Assignee
Remedy Plan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remedy Plan Inc filed Critical Remedy Plan Inc
Priority to US17/774,583 priority Critical patent/US12612368B2/en
Assigned to REMEDY PLAN, INC. reassignment REMEDY PLAN, INC. ASSIGNMENT OF ASSIGNOR'S INTEREST Assignors: DE JESÚS DIAZ, Dennise Alexandra, CRIMMINS, Gregory Thomas, ROBB, Caroline Mae, BHURRUTH-ALCOR, YUSHMA
Publication of US20230023124A1 publication Critical patent/US20230023124A1/en
Application granted granted Critical
Publication of US12612368B2 publication Critical patent/US12612368B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
US17/774,583 2019-11-06 2020-11-06 Cancer treatments targeting cancer stem cells Active 2043-08-20 US12612368B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/774,583 US12612368B2 (en) 2019-11-06 2020-11-06 Cancer treatments targeting cancer stem cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962931531P 2019-11-06 2019-11-06
US17/774,583 US12612368B2 (en) 2019-11-06 2020-11-06 Cancer treatments targeting cancer stem cells
PCT/US2020/059329 WO2021092322A1 (en) 2019-11-06 2020-11-06 Cancer treatments targeting cancer stem cells

Publications (2)

Publication Number Publication Date
US20230023124A1 US20230023124A1 (en) 2023-01-26
US12612368B2 true US12612368B2 (en) 2026-04-28

Family

ID=73643356

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/774,583 Active 2043-08-20 US12612368B2 (en) 2019-11-06 2020-11-06 Cancer treatments targeting cancer stem cells

Country Status (13)

Country Link
US (1) US12612368B2 (https=)
EP (1) EP4055008A1 (https=)
JP (2) JP7690470B2 (https=)
KR (1) KR20220110744A (https=)
CN (2) CN119930509A (https=)
AU (1) AU2020378067A1 (https=)
BR (1) BR112022008753A2 (https=)
CA (1) CA3157315A1 (https=)
CO (1) CO2022007910A2 (https=)
IL (1) IL292718A (https=)
MX (1) MX2022005445A (https=)
PH (1) PH12022551081A1 (https=)
WO (1) WO2021092322A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12522587B2 (en) 2018-05-04 2026-01-13 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
EP4055008A1 (en) 2019-11-06 2022-09-14 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
JP2024518089A (ja) * 2021-05-13 2024-04-24 リメディー プラン，インコーポレーテッド Ｎａｍｐｔ阻害剤とその使用
CN119234351A (zh) 2022-09-01 2024-12-31 株式会社Lg新能源 二次电池和包括该二次电池的装置
CN116139141A (zh) * 2022-12-14 2023-05-23 复旦大学 Agk2促进肝癌的免疫治疗的用途

Citations (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0015773A2 (en) 1979-03-12 1980-09-17 Warner-Lambert Company N-(6-((acylaminoacylamino or aminoacylamino)phenyl) 1,2-dihydro-2-oxonicotinyl)penicillin compounds, processes for their production and compositions containing them
EP0015771A1 (en) 1979-03-12 1980-09-17 Warner-Lambert Company N-(6-((acylaminoacylamino or aminoacylamino)phenyl)-1,2-dihydro-2-oxonicotinyl) cephalosporin compounds, processes for their production, and compositions containing the same
JPS56115784A (en) 1980-02-15 1981-09-11 Tanabe Seiyaku Co Ltd Novel pyridinecarboxamide derivative and its preparation
US4315014A (en) 1980-09-24 1982-02-09 Warner-Lambert Company Antibacterial amide compounds and pharmaceutical composition containing the same
US4315858A (en) 1980-09-24 1982-02-16 Warner-Lambert Company Antibacterial amide compounds
JPH02127512A (ja) 1988-11-07 1990-05-16 Motoo Takayanagi ピラジン環含有芳香族ポリアミド繊維
JPH02127429A (ja) 1988-11-07 1990-05-16 Motoo Takayanagi ピラジン環含有芳香族ポリアミドおよびその製造法
GB2273930A (en) 1992-12-30 1994-07-06 Glaxo Group Ltd Benzanilide derivatives
EP0706795A2 (en) 1994-09-21 1996-04-17 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
WO1997048397A1 (en) 1996-06-20 1997-12-24 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
WO1997048696A1 (en) 1996-06-20 1997-12-24 Klinge Pharma Gmbh Pyridyl alkene- and pyridyl alkine- acid amides as cytostatics and immunosuppressives
JPH10152462A (ja) 1996-09-30 1998-06-09 Mitsui Chem Inc 分化誘導剤
JPH11302173A (ja) 1998-04-16 1999-11-02 Mitsui Chem Inc ヒストン脱アセチル化酵素阻害剤
JP2000256194A (ja) 1999-01-06 2000-09-19 Mitsui Chemicals Inc 核内レセプタ作動薬およびその効果増強剤
WO2001011965A1 (en) 1999-08-18 2001-02-22 Aventis Cropscience Gmbh Fungicides
WO2002060875A1 (en) 2001-01-31 2002-08-08 Pfizer Products Inc. Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
WO2003003009A1 (en) 2001-06-29 2003-01-09 7Tm Pharma A/S Use of metal-ion chelates in validating biological molecules as drug targets in test animal models
WO2003003008A1 (en) 2001-06-29 2003-01-09 7Tm Pharma A/S Chemical libraries useful for drug discovery processes
WO2003055477A1 (en) 2001-12-21 2003-07-10 7Tm Pharma A/S Method for the treatment of mc receptor related disorders with a chelate and/or a chelator
WO2003059913A1 (en) 2002-01-10 2003-07-24 Bayer Healthcare Ag Roh-kinase inhibitors
WO2003080054A1 (en) 2002-03-27 2003-10-02 Fujisawa Deutschland Gmbh Use of pyridyl amides as inhibitors of angiogenesis
WO2004058234A2 (en) 2002-12-27 2004-07-15 Schering Aktiengesellschaft Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors
WO2005012299A1 (de) 2003-07-30 2005-02-10 Bayer Healthcare Ag N-biarylamide
WO2006023844A2 (en) 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
WO2006028958A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
WO2006067446A1 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Pyridine carboxamide derivatives for use as anticancer agents
WO2006067445A2 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
WO2006075160A1 (en) 2005-01-15 2006-07-20 Astrazeneca Ab N-phenyl-4-pyridin-2-yl-benzamide derivatives as histone deacylase (hdac) inhibitors for the treatment of cancer
WO2006077387A2 (en) 2005-01-20 2006-07-27 Astrazeneca Ab Novel benzamide derivatives
WO2006130403A1 (en) 2005-06-02 2006-12-07 Bayer Cropscience Ag Phenylalkyl substituted heteroaryl devivatives
WO2007009715A1 (en) 2005-07-18 2007-01-25 Novartis Ag 2-cyano-pyrimidines and -triazines as cysteine protease inhibitors
WO2007024922A1 (en) 2005-08-23 2007-03-01 Irm Llc Immunosuppressant compounds and compositions
WO2007062028A2 (en) 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Treatment of qt interval prolongation and diseases associated therewith
WO2007072999A1 (en) 2005-12-22 2007-06-28 Nihon Nohyaku Co., Ltd Pyrazinecarboxamide derivatives and plant disease controlling agents containing the same
WO2007076055A2 (en) 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
WO2007125331A2 (en) 2006-04-26 2007-11-08 Cancer Research Technology Limited Amino-ethyl-amino-aryl (aeaa) compounds and their use
WO2008016643A2 (en) 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
WO2008024963A1 (en) 2006-08-24 2008-02-28 Serenex, Inc. Benzene, pyridine, and pyridazine derivatives
WO2008025857A2 (en) 2006-09-01 2008-03-06 Topotarget Switzerland Sa New method for the treatment of inflammatory diseases
FR2904827B1 (fr) 2006-08-11 2008-09-19 Sanofi Aventis Sa Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antiganistes des recepteurs a l'urotensine ii
FR2921657A1 (fr) 2007-09-28 2009-04-03 Sanofi Aventis Sa Derives de nicotinamide, leur preparation et leur application en therapeutique
WO2009053694A1 (en) 2007-10-24 2009-04-30 Cancer Research Technology Limited Therapeutic oxy-phenyl-aryl compounds and their use
US20090131640A1 (en) 2007-11-21 2009-05-21 Bio-Rad Laboratories, Inc. Photoluminescent metal complexes for protein staining
WO2009076142A2 (en) 2007-12-07 2009-06-18 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids
WO2009109610A1 (en) 2008-03-05 2009-09-11 Topotarget Switzerland S.A. Use of nad information inhibitors for the treatment of ischemia-reperfusion injury
WO2009126863A2 (en) 2008-04-11 2009-10-15 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
WO2010056549A1 (en) 2008-10-29 2010-05-20 Sirtris Pharmaceuticals, Inc. Pyridine, bicyclic pyridine and related analogs as sirtuin modulators
WO2012006475A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2012014994A1 (ja) 2010-07-30 2012-02-02 ダイトーケミックス株式会社 ナフタレン誘導体
WO2012024179A1 (en) 2010-08-18 2012-02-23 Merck Sharp & Dohme Corp. Substituted amide derivatives as dgat-1 inhibitors
WO2012031197A1 (en) 2010-09-03 2012-03-08 Forma Therapeutics, Inc. Novel compounds and compositions for the inhibition of nampt
WO2012043891A1 (ja) 2010-09-30 2012-04-05 ダイトーケミックス株式会社 眼疾患処置薬
WO2012054110A2 (en) 2010-07-07 2012-04-26 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2012143415A1 (en) 2011-04-21 2012-10-26 Glaxosmithkline Llc Tetrahydroquinoline derivatives useful as bromodomain inhibitors
WO2012156919A1 (en) 2011-05-16 2012-11-22 Koninklijke Philips Electronics N.V. Bio-orthogonal drug activation
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
WO2013028445A1 (en) 2011-08-19 2013-02-28 Glaxosmithkline Llc Fatty acid synthase inhibitors
EP2589292A1 (en) 2011-11-02 2013-05-08 Bayer CropScience AG Compounds with nematicidal activity
WO2013064460A1 (en) 2011-11-02 2013-05-10 Bayer Intellectual Property Gmbh Compounds with nematicidal activity
US8461342B2 (en) 2007-12-07 2013-06-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
WO2013083991A1 (en) 2011-12-06 2013-06-13 Imperial Innovations Limited Novel compounds and their use in therapy
JP2013530199A (ja) 2010-07-06 2013-07-25 ノバルティス アーゲー キナーゼ阻害剤として有用な環状エーテル化合物
US8524767B2 (en) 2005-12-28 2013-09-03 Vertex Pharmaceuticals Incorporated Modulators of ATP binding cassette transporters
WO2014008214A1 (en) 2012-07-02 2014-01-09 Biogen Idec Ma Inc. Biaryl-containing compounds as inverse agonists of ror-gamma receptors
WO2014081300A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Channel protein activatable liposomes
WO2014081299A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Activatable liposomes
WO2014081303A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Chemically cleavable group
WO2014081301A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Bio-orthogonal drug activation
JP2014518223A (ja) 2011-06-20 2014-07-28 アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッド 化合物とその治療用途
WO2014145642A2 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Nrf2 small molecule inhibitors for cancer therapy
WO2014145873A2 (en) 2013-03-15 2014-09-18 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
WO2014203217A1 (en) 2013-06-21 2014-12-24 Lupin Limited Substituted heterocyclic compounds as crac modulators
WO2015040424A1 (en) 2013-09-23 2015-03-26 Vernalis (R&D) Limited Tetrahydroisoquinoline compounds and their use as pyruvate dehydrogenase kinase inhibitors
WO2015078949A1 (en) 2013-11-27 2015-06-04 Euroscreen Sa Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
WO2015117053A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
US20150231142A1 (en) 2009-10-22 2015-08-20 Vertex Pharmaceuticals Incorporated Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
WO2015127137A1 (en) 2014-02-19 2015-08-27 Aldea Pharmaceuticals, Inc. Mitochondrial aldehyde dehydrogenase 2 (aldh2) binding polycyclic amides and their use for the treatment of cancer
WO2015154820A1 (en) 2014-04-11 2015-10-15 Panoptes Pharma Gmbh Anti-inflammatory agents as virostatic compounds
JP5799117B2 (ja) 2013-02-05 2015-10-21 大日本住友製薬株式会社 ウラシル誘導体からなる医薬
WO2017009650A1 (en) 2015-07-14 2017-01-19 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
JP2017516774A (ja) 2014-05-22 2017-06-22 ジェンザイム・コーポレーション Ｎａｍｐｔ阻害剤および方法
WO2017141036A1 (en) 2016-02-18 2017-08-24 Mission Therapeutics Limited Novel compounds
WO2017150209A1 (ja) 2016-02-29 2017-09-08 住友化学株式会社 複素環化合物
WO2018017589A1 (en) 2016-07-19 2018-01-25 The General Hospital Corporation Compounds for targeting cancer stem cells
WO2018075842A1 (en) 2016-10-20 2018-04-26 Bristol-Myers Squibb Company Condensed benzodiazepine derivatives and conjugates made therefrom
WO2018101424A1 (ja) 2016-12-01 2018-06-07 住友化学株式会社 複素環化合物及びそれを含有する有害節足動物防除組成物
WO2018133795A1 (zh) 2017-01-17 2018-07-26 中国科学院合肥物质科学研究院 一种ezh2抑制剂及其用途
WO2018190352A1 (ja) 2017-04-11 2018-10-18 三井化学アグロ株式会社 ピリドン化合物およびそれを有効成分とする農園芸用殺菌剤
WO2018194885A1 (en) 2017-04-18 2018-10-25 Eli Lilly And Company Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
WO2018216640A1 (ja) 2017-05-22 2018-11-29 小野薬品工業株式会社 Ｅｐ４アンタゴニスト
US20180370909A1 (en) 2015-12-15 2018-12-27 University Of Miami Inhibitors of tnf superfamily costimulatory interactions and methods for uses of the same
JP2019512503A (ja) 2016-03-17 2019-05-16 インダストリー−アカデミック コオペレイション ファウンデーション、ヨンセイ ユニバーシティ ニコチンアミドホスホリボシルトランスフェラーゼ抑制用新規化合物及びこれを含む組成物
WO2019148125A1 (en) 2018-01-29 2019-08-01 Capulus Therapeutics, Llc Srebp inhibitors comprising a 6-membered central ring
WO2019213570A1 (en) 2018-05-04 2019-11-07 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
WO2020054712A1 (ja) 2018-09-12 2020-03-19 日本化薬株式会社 有害生物防除剤
KR102210267B1 (ko) 2020-05-26 2021-02-01 (주)피엔에이치테크 유기발광 화합물 및 이를 포함하는 유기발광소자
WO2021092322A1 (en) 2019-11-06 2021-05-14 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
WO2022050286A1 (ja) 2020-09-02 2022-03-10 国立大学法人東京大学 有機半導体材料
US20240376074A1 (en) 2021-05-13 2024-11-14 Remedy Plan, Inc. Nampt inhibitors and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2872652A1 (en) 2012-05-07 2013-11-14 The General Hospital Corporation Novel compositions and uses of anti-hypertension agents for cancer therapy
WO2014169073A1 (en) 2013-04-09 2014-10-16 Massachusetts Institute Of Technology Drug delivery polymer and uses thereof

Patent Citations (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0015773A2 (en) 1979-03-12 1980-09-17 Warner-Lambert Company N-(6-((acylaminoacylamino or aminoacylamino)phenyl) 1,2-dihydro-2-oxonicotinyl)penicillin compounds, processes for their production and compositions containing them
EP0015771A1 (en) 1979-03-12 1980-09-17 Warner-Lambert Company N-(6-((acylaminoacylamino or aminoacylamino)phenyl)-1,2-dihydro-2-oxonicotinyl) cephalosporin compounds, processes for their production, and compositions containing the same
US4278681A (en) 1979-03-12 1981-07-14 Warner-Lambert Co. Antibacterial amide compounds and means for using the same
JPS56115784A (en) 1980-02-15 1981-09-11 Tanabe Seiyaku Co Ltd Novel pyridinecarboxamide derivative and its preparation
US4315014A (en) 1980-09-24 1982-02-09 Warner-Lambert Company Antibacterial amide compounds and pharmaceutical composition containing the same
US4315858A (en) 1980-09-24 1982-02-16 Warner-Lambert Company Antibacterial amide compounds
JPH02127512A (ja) 1988-11-07 1990-05-16 Motoo Takayanagi ピラジン環含有芳香族ポリアミド繊維
JPH02127429A (ja) 1988-11-07 1990-05-16 Motoo Takayanagi ピラジン環含有芳香族ポリアミドおよびその製造法
GB2273930A (en) 1992-12-30 1994-07-06 Glaxo Group Ltd Benzanilide derivatives
EP0706795A2 (en) 1994-09-21 1996-04-17 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
WO1997048397A1 (en) 1996-06-20 1997-12-24 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
WO1997048696A1 (en) 1996-06-20 1997-12-24 Klinge Pharma Gmbh Pyridyl alkene- and pyridyl alkine- acid amides as cytostatics and immunosuppressives
JPH10152462A (ja) 1996-09-30 1998-06-09 Mitsui Chem Inc 分化誘導剤
JPH11302173A (ja) 1998-04-16 1999-11-02 Mitsui Chem Inc ヒストン脱アセチル化酵素阻害剤
JP2000256194A (ja) 1999-01-06 2000-09-19 Mitsui Chemicals Inc 核内レセプタ作動薬およびその効果増強剤
WO2001011965A1 (en) 1999-08-18 2001-02-22 Aventis Cropscience Gmbh Fungicides
WO2002060875A1 (en) 2001-01-31 2002-08-08 Pfizer Products Inc. Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
WO2003003009A1 (en) 2001-06-29 2003-01-09 7Tm Pharma A/S Use of metal-ion chelates in validating biological molecules as drug targets in test animal models
WO2003003008A1 (en) 2001-06-29 2003-01-09 7Tm Pharma A/S Chemical libraries useful for drug discovery processes
WO2003055477A1 (en) 2001-12-21 2003-07-10 7Tm Pharma A/S Method for the treatment of mc receptor related disorders with a chelate and/or a chelator
WO2003059913A1 (en) 2002-01-10 2003-07-24 Bayer Healthcare Ag Roh-kinase inhibitors
WO2003080054A1 (en) 2002-03-27 2003-10-02 Fujisawa Deutschland Gmbh Use of pyridyl amides as inhibitors of angiogenesis
WO2004058234A2 (en) 2002-12-27 2004-07-15 Schering Aktiengesellschaft Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors
WO2005012299A1 (de) 2003-07-30 2005-02-10 Bayer Healthcare Ag N-biarylamide
WO2006023844A2 (en) 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
JP2008510726A (ja) 2004-08-20 2008-04-10 エントレメッド インコーポレイテッド プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法
WO2006028958A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
WO2006067446A1 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Pyridine carboxamide derivatives for use as anticancer agents
WO2006067445A2 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
WO2006075160A1 (en) 2005-01-15 2006-07-20 Astrazeneca Ab N-phenyl-4-pyridin-2-yl-benzamide derivatives as histone deacylase (hdac) inhibitors for the treatment of cancer
WO2006077387A2 (en) 2005-01-20 2006-07-27 Astrazeneca Ab Novel benzamide derivatives
WO2006130403A1 (en) 2005-06-02 2006-12-07 Bayer Cropscience Ag Phenylalkyl substituted heteroaryl devivatives
WO2007009715A1 (en) 2005-07-18 2007-01-25 Novartis Ag 2-cyano-pyrimidines and -triazines as cysteine protease inhibitors
WO2007024922A1 (en) 2005-08-23 2007-03-01 Irm Llc Immunosuppressant compounds and compositions
WO2007062028A2 (en) 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Treatment of qt interval prolongation and diseases associated therewith
WO2007072999A1 (en) 2005-12-22 2007-06-28 Nihon Nohyaku Co., Ltd Pyrazinecarboxamide derivatives and plant disease controlling agents containing the same
WO2007076055A2 (en) 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
US20090233934A1 (en) 2005-12-22 2009-09-17 Masatsugu Oda Pyrazinecarboxamide Derivatives and Plant Disease Controlling Agents Containing the Same
US8524767B2 (en) 2005-12-28 2013-09-03 Vertex Pharmaceuticals Incorporated Modulators of ATP binding cassette transporters
WO2007125331A2 (en) 2006-04-26 2007-11-08 Cancer Research Technology Limited Amino-ethyl-amino-aryl (aeaa) compounds and their use
WO2008016643A2 (en) 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
FR2904827B1 (fr) 2006-08-11 2008-09-19 Sanofi Aventis Sa Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antiganistes des recepteurs a l'urotensine ii
WO2008024963A1 (en) 2006-08-24 2008-02-28 Serenex, Inc. Benzene, pyridine, and pyridazine derivatives
WO2008025857A2 (en) 2006-09-01 2008-03-06 Topotarget Switzerland Sa New method for the treatment of inflammatory diseases
FR2921657A1 (fr) 2007-09-28 2009-04-03 Sanofi Aventis Sa Derives de nicotinamide, leur preparation et leur application en therapeutique
US20100222319A1 (en) 2007-09-28 2010-09-02 Sanofi-Aventis Nicotinamide derivatives, preparation thereof and therapeutic use thereof
WO2009053694A1 (en) 2007-10-24 2009-04-30 Cancer Research Technology Limited Therapeutic oxy-phenyl-aryl compounds and their use
US20090131640A1 (en) 2007-11-21 2009-05-21 Bio-Rad Laboratories, Inc. Photoluminescent metal complexes for protein staining
WO2009076142A2 (en) 2007-12-07 2009-06-18 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids
US8461342B2 (en) 2007-12-07 2013-06-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
WO2009109610A1 (en) 2008-03-05 2009-09-11 Topotarget Switzerland S.A. Use of nad information inhibitors for the treatment of ischemia-reperfusion injury
WO2009126863A2 (en) 2008-04-11 2009-10-15 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
WO2010056549A1 (en) 2008-10-29 2010-05-20 Sirtris Pharmaceuticals, Inc. Pyridine, bicyclic pyridine and related analogs as sirtuin modulators
US20150231142A1 (en) 2009-10-22 2015-08-20 Vertex Pharmaceuticals Incorporated Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
JP2013530199A (ja) 2010-07-06 2013-07-25 ノバルティス アーゲー キナーゼ阻害剤として有用な環状エーテル化合物
WO2012006475A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2012054110A2 (en) 2010-07-07 2012-04-26 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2012014994A1 (ja) 2010-07-30 2012-02-02 ダイトーケミックス株式会社 ナフタレン誘導体
WO2012024179A1 (en) 2010-08-18 2012-02-23 Merck Sharp & Dohme Corp. Substituted amide derivatives as dgat-1 inhibitors
WO2012031197A1 (en) 2010-09-03 2012-03-08 Forma Therapeutics, Inc. Novel compounds and compositions for the inhibition of nampt
WO2012043891A1 (ja) 2010-09-30 2012-04-05 ダイトーケミックス株式会社 眼疾患処置薬
WO2012143415A1 (en) 2011-04-21 2012-10-26 Glaxosmithkline Llc Tetrahydroquinoline derivatives useful as bromodomain inhibitors
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
WO2012156919A1 (en) 2011-05-16 2012-11-22 Koninklijke Philips Electronics N.V. Bio-orthogonal drug activation
JP2014518223A (ja) 2011-06-20 2014-07-28 アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッド 化合物とその治療用途
WO2013028445A1 (en) 2011-08-19 2013-02-28 Glaxosmithkline Llc Fatty acid synthase inhibitors
WO2013064460A1 (en) 2011-11-02 2013-05-10 Bayer Intellectual Property Gmbh Compounds with nematicidal activity
EP2589292A1 (en) 2011-11-02 2013-05-08 Bayer CropScience AG Compounds with nematicidal activity
WO2013083991A1 (en) 2011-12-06 2013-06-13 Imperial Innovations Limited Novel compounds and their use in therapy
WO2014008214A1 (en) 2012-07-02 2014-01-09 Biogen Idec Ma Inc. Biaryl-containing compounds as inverse agonists of ror-gamma receptors
WO2014081300A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Channel protein activatable liposomes
WO2014081299A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Activatable liposomes
WO2014081303A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Chemically cleavable group
WO2014081301A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Bio-orthogonal drug activation
JP5799117B2 (ja) 2013-02-05 2015-10-21 大日本住友製薬株式会社 ウラシル誘導体からなる医薬
WO2014145873A2 (en) 2013-03-15 2014-09-18 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
WO2014145642A2 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Nrf2 small molecule inhibitors for cancer therapy
WO2014203217A1 (en) 2013-06-21 2014-12-24 Lupin Limited Substituted heterocyclic compounds as crac modulators
WO2015040424A1 (en) 2013-09-23 2015-03-26 Vernalis (R&D) Limited Tetrahydroisoquinoline compounds and their use as pyruvate dehydrogenase kinase inhibitors
WO2015078949A1 (en) 2013-11-27 2015-06-04 Euroscreen Sa Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
WO2015117053A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
WO2015127137A1 (en) 2014-02-19 2015-08-27 Aldea Pharmaceuticals, Inc. Mitochondrial aldehyde dehydrogenase 2 (aldh2) binding polycyclic amides and their use for the treatment of cancer
WO2015154820A1 (en) 2014-04-11 2015-10-15 Panoptes Pharma Gmbh Anti-inflammatory agents as virostatic compounds
JP2017516774A (ja) 2014-05-22 2017-06-22 ジェンザイム・コーポレーション Ｎａｍｐｔ阻害剤および方法
WO2017009650A1 (en) 2015-07-14 2017-01-19 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
US20180370909A1 (en) 2015-12-15 2018-12-27 University Of Miami Inhibitors of tnf superfamily costimulatory interactions and methods for uses of the same
WO2017141036A1 (en) 2016-02-18 2017-08-24 Mission Therapeutics Limited Novel compounds
WO2017150209A1 (ja) 2016-02-29 2017-09-08 住友化学株式会社 複素環化合物
EP3431472B1 (en) 2016-03-17 2023-05-03 Checkmate Therapeutics Inc. Novel compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same
JP2019512503A (ja) 2016-03-17 2019-05-16 インダストリー−アカデミック コオペレイション ファウンデーション、ヨンセイ ユニバーシティ ニコチンアミドホスホリボシルトランスフェラーゼ抑制用新規化合物及びこれを含む組成物
WO2018017589A1 (en) 2016-07-19 2018-01-25 The General Hospital Corporation Compounds for targeting cancer stem cells
WO2018075842A1 (en) 2016-10-20 2018-04-26 Bristol-Myers Squibb Company Condensed benzodiazepine derivatives and conjugates made therefrom
WO2018101424A1 (ja) 2016-12-01 2018-06-07 住友化学株式会社 複素環化合物及びそれを含有する有害節足動物防除組成物
CN108314677B (zh) 2017-01-17 2020-06-30 安徽中科拓苒药物科学研究有限公司 一种ezh2抑制剂及其用途
WO2018133795A1 (zh) 2017-01-17 2018-07-26 中国科学院合肥物质科学研究院 一种ezh2抑制剂及其用途
WO2018190352A1 (ja) 2017-04-11 2018-10-18 三井化学アグロ株式会社 ピリドン化合物およびそれを有効成分とする農園芸用殺菌剤
WO2018194885A1 (en) 2017-04-18 2018-10-25 Eli Lilly And Company Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
WO2018216640A1 (ja) 2017-05-22 2018-11-29 小野薬品工業株式会社 Ｅｐ４アンタゴニスト
WO2019148125A1 (en) 2018-01-29 2019-08-01 Capulus Therapeutics, Llc Srebp inhibitors comprising a 6-membered central ring
US20220324842A1 (en) 2018-05-04 2022-10-13 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
WO2019213570A1 (en) 2018-05-04 2019-11-07 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
WO2020054712A1 (ja) 2018-09-12 2020-03-19 日本化薬株式会社 有害生物防除剤
WO2021092322A1 (en) 2019-11-06 2021-05-14 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
KR102210267B1 (ko) 2020-05-26 2021-02-01 (주)피엔에이치테크 유기발광 화합물 및 이를 포함하는 유기발광소자
WO2022050286A1 (ja) 2020-09-02 2022-03-10 国立大学法人東京大学 有機半導体材料
US20240376074A1 (en) 2021-05-13 2024-11-14 Remedy Plan, Inc. Nampt inhibitors and uses thereof

Non-Patent Citations (92)

* Cited by examiner, † Cited by third party
Title
[No Author Listed], Benzamide, 3-(1-acetyl-1,2,3,4-tetrahydro-6-quinolinyl)-N-(3-Isoxazolylmethyl)-N-methyl-. CAS Registry File RN 2109509-83-1. STN Entry Date Aug. 7, 2017. 1 page.
[No Author Listed], Benzamide, 4-(1-acetyl-2,3-dihydro-1H-indol-5-yl)-N-(1-phenylethyl)-. CAS Registry File RN 1359334-09-0. STN Entry Date Mar. 2, 2012. 1 page.
[No Author Listed], Benzamide, 4-(1-acetyl-2,3-dihydro-1H-indol-5-yl)-N-(2-furanylmethyl)-. CAS Registry File RN 1358036-86-8. STN Entry Date Feb. 28, 2012. 1 page.
[No Author Listed], Benzamide, 4-(1-acetyl-2,3-dihydro-1H-indol-5-yl)-N-(2-thienylmethyl)-. CAS Registry File RN 1358948-71-6. STN Entry Date Mar. 1, 2012. 1 page.
[No Author Listed], Benzamide, 4-(1-acetyl-2,3-dihydro-1H-indol-5-yl)-N-[(1,3,5-trimethyl-1H-pyrazol-4-yl)methyl]-. CAS Registry File RN 1189708-01-7. STN Entry Date Oct. 23, 2009. 1 page.
[No Author Listed], Benzamide, 4-(1-acetyl-2,3-dihydro-1H-indol-5-yl)-N-[(5-methyl-2-furanyl)methyl]-. CAS Registry File RN 1358617-91-0. STN Entry Date Feb. 29, 2012. 1 page.
[No Author Listed], Benzamide, 4-[2,3-dihydro-1-(1-oxopropyl)-1H-indol-5-yl]-N-(2- thienylmethyl)-. CAS Registry File RN 1358617-23-8. STN Entry Date Feb. 29, 2012. 1 page.
[No Author Listed], Benzamide, 4-[2,3-dihydro-1-(1-oxopropyl)-1H-indol-5-yl]-N-[(1,3,5-trimethyl-1H-pyrazol-4-yl)methyl]-. CAS Registry File RN 1189881-08-0. STN Entry Date Oct. 25, 2009. 1 page.
[No Author Listed], Benzamide, 4-[2,3-dihydro-1-(1-oxopropyl)-1H-indol-5-yl]-N-[(5-methyl-2-furanyl)methyl]-. CAS Registry File RN 1358562-49-8. STN Entry Date Feb. 29, 2012. 1 page.
[No Author Listed], CAS Registry File RN 1357756-25-2. STN Entry Date Feb. 28, 2012.
[No Author Listed], CAS Registry File RN 1357757-07-3. STN Entry Date Feb. 28, 2012.
[No Author Listed], CAS Registry File RN 1358017-42-1. STN Entry Date Feb. 28, 2012.
[No Author Listed], CAS Registry File RN 1358036-74-4. STN Entry Date Feb. 28, 2012.
[No Author Listed], CAS Registry File RN 1358036-89-1. STN Entry Date Feb. 28, 2012.
[No Author Listed], CAS Registry File RN 1358302-05-2. STN Entry Date Feb. 29, 2012.
[No Author Listed], CAS Registry File RN 1358368-86-1. STN Entry Date Feb. 29, 2012.
[No Author Listed], CAS Registry File RN 1358383-49-9. STN Entry Date Feb. 29, 2012.
[No Author Listed], CAS Registry File RN 1358383-89-7. STN Entry Date Feb. 29, 2012.
[No Author Listed], CAS Registry File RN 1358384-07-2. STN Entry Date Feb. 29, 2012.
[No Author Listed], CAS Registry File RN 1358384-20-9. STN Entry Date Feb. 29, 2012.
[No Author Listed], CAS Registry File RN 1358480-80-4. STN Entry Date Feb. 29, 2012.
[No Author Listed], CAS Registry File RN 1358481-15-8. STN Entry Date Feb. 29, 2012.
[No Author Listed], CAS Registry File RN 1358481-23-8. STN Entry Date Feb. 29, 2012.
[No Author Listed], CAS Registry File RN 1358617-00-1. STN Entry Date Feb. 29, 2012.
[No Author Listed], CAS Registry File RN 1358617-31-8. STN Entry Date Feb. 29, 2012.
[No Author Listed], CAS Registry File RN 1358618-13-9. STN Entry Date Feb. 29, 2012.
[No Author Listed], CAS Registry File RN 1358668-90-2. STN Entry Date Feb. 29, 2012.
[No Author Listed], CAS Registry File RN 1358807-11-0. STN Entry Date Feb. 29, 2012.
[No Author Listed], CAS Registry File RN 1358814-23-9. STN Entry Date Feb. 29, 2012.
[No Author Listed], CAS Registry File RN 1358814-41-1. STN Entry Date Feb. 29, 2012.
[No Author Listed], CAS Registry File RN 1358931-36-8. STN Entry Date Mar. 1, 2012.
[No Author Listed], CAS Registry File RN 1358942-68-3. STN Entry Date Mar. 1, 2012.
[No Author Listed], CAS Registry File RN 1358948-13-6. STN Entry Date Mar. 1, 2012.
[No Author Listed], CAS Registry File RN 1358948-48-7. STN Entry Date Mar. 1, 2012.
[No Author Listed], CAS Registry File RN 1359202-70-2. STN Entry Date Mar. 1, 2012.
[No Author Listed], CAS Registry File RN 1359351-05-5. STN Entry Date Mar. 2, 2012.
[No Author Listed], CAS Registry File RN 1359369-01-9. STN Entry Date Mar. 2, 2012.
[No Author Listed], CAS Registry File RN 1359381-05-7. STN Entry Date Mar. 2, 2012.
[No Author Listed], CAS Registry File RN 1359381-43-3. STN Entry Date Mar. 2, 2012.
[No Author Listed], CAS Registry File RN 1359381-51-3. STN Entry Date Mar. 2, 2012.
Asciutti et al., Diverse mechanisms of Wnt activation and effects of pathway inhibition on proliferation of human gastric carcinoma cells. Oncogene. Feb. 24, 2011;30(8):956-66. doi: 10.1038/onc.2010.475. Epub Nov. 1, 2010.
Audrito et al., NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation. Front Oncol. Mar. 19, 2020;10:358. doi: 10.3389/fonc.2020.00358.
Benito-Martin et al., Endogenous NAMPT dampens chemokine expression and apoptotic responses in stressed tubular cells. Biochim Biophys Acta. Feb. 2014;1842(2):293-303. doi: 10.1016/j.bbadis.2013.11.022. Epub Nov. 25, 2013.
Ben-Porath et al., An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. May 2008;40(5):499-507. doi: 10.1038/ng.127.
Bermudez et al., Leukocyte Overexpression of Intracellular NAMPT Attenuates Atherosclerosis by Regulating PPARγ-Dependent Monocyte Differentiation and Function. Arterioscler Thromb Vasc Biol. Jun. 2017;37(6):1157-1167. doi: 10.1161/ATVBAHA.116.308187. Epub Apr. 13, 2017.
Bonnet et al., Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. Jul. 1997;3(7):730-7. doi: 10.1038/nm0797-730.
Brucoli et al., Efficient solid-phase synthesis of a library of distamycin analogs containing novel biaryl motifs on SynPhase Lanterns. J Comb Chem. Jul.-Aug. 2009;11(4):576-86. doi: 10.1021/cc900009r.
Busso et al., Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One. May 21, 2008;3(5):e2267. doi: 10.1371/journal.pone.0002267.
Canadian Office Action, mailed Nov. 14, 2024, in connection with Application No. 3,135,740.
Cancer Genome Atlas Research Network, Comprehensive molecular characterization of gastric adenocarcinoma. Nature. Sep. 11, 2014;513(7517):202-9. doi: 10.1038/nature13480. Epub Jul. 23, 2014.
Chen et al., A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. Aug. 23, 2012;488(7412):522-6. doi: 10.1038/nature11287.
Chen et al., Endogenous Nampt upregulation is associated with diabetic nephropathy inflammatory-fibrosis through the NF-κB p65 and Sirt1 pathway; NMN alleviates diabetic nephropathy inflammatory-fibrosis by inhibiting endogenous Nampt. Exp Ther Med. Nov. 2017;14(5):4181-4193. doi: 10.3892/etm.2017.5098. Epub Sep. 1, 2017.
Chen et al., NAMPT inhibitor protects ischemic neuronal injury in rat brain via anti-neuroinflammation. Neuroscience. Jul. 25, 2017;356:193-206. doi: 10.1016/j.neuroscience.2017.05.022. Epub May 19, 2017.
Colombo et al., Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis. J Mol Med (Berl). Apr. 2020;98(4):595-612. doi: 10.1007/s00109-020-01892-0. Epub Apr. 27, 2020.
Esposito et al., The NAMPT inhibitor FK866 reverts the damage in spinal cord injury. J Neuroinflammation. Apr. 10, 2012;9:66. doi: 10.1186/1742-2094-9-66.
Evans et al., Suppression of leukocyte infiltration and cartilage degradation by selective inhibition of pre-B cell colony-enhancing factor/visfatin/nicotinamide phosphoribosyltransferase: Apo866-mediated therapy in human fibroblasts and murine collagen-induced arthritis. Arthritis Rheum. Jul. 2011;63(7):1866-77. doi: 10.1002/art.30338.
Extended European Search Report, mailed Oct. 19, 2021, in connection with Application No. 19796696.3.
Galli et al., Recent Advances in NAMPT Inhibitors: A Novel Immunotherapie Strategy. Front Pharmacol. May 12, 2020;11:656. doi: 10.3389/fphar.2020.00656. 20 pages.
Gerner et al., NAD metabolism fuels human and mouse intestinal inflammation. Gut. Oct. 2018;67(10):1813-1823. doi: 10.1136/gutjnl-2017-314241. Epub Sep. 6, 2017.
Gerner et al., Targeting NAD immunometabolism limits severe graft-versus-host disease and has potent antileukemic activity. Leukemia. Jul. 2020;34(7):1885-1897. doi: 10.1038/s41375-020-0709-0. Epub Jan. 23, 2020.
Golub et al., Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. Oct. 15, 1999;286(5439):531-7. doi: 10.1126/science.286.5439.531.
Guinney et al., The consensus molecular subtypes of colorectal cancer. Nat Med. Nov. 2015;21(11):1350-6. doi: 10.1038/nm.3967. Epub Oct. 12, 2015.
Hadjimichael et al., Common stemness regulators of embryonic and cancer stem cells. World J Stem Cells. Oct. 26, 2015;7(9):1150-84. doi: 10.4252/wjsc.v7.i9.1150.
Honma et al., Antiallergic agents. 2. N-(1H-tetrazol-5-yl)-6-phenyl-2-pyridinecarboxamides. J Med Chem. Oct. 1983;26(10):1499-504. doi: 10.1021/jm00364a026.
International Preliminary Report on Patentability, mailed May 19, 2022, in connection with Application No. PCT/US2020/059329.
International Preliminary Report on Patentability, mailed Nov. 19, 2020, in connection with Application No. PCT/US2019/030664.
International Preliminary Report on Patentability, mailed Nov. 23, 2023, in connection with Application No. PCT/US2022/029259.
International Search Report and Written Opinion, mailed Aug. 1, 2022, in connection with Application No. PCT/US2022/029259.
International Search Report and Written Opinion, mailed Aug. 19, 2019, in connection with Application No. PCT/US2019/030664.
International Search Report and Written Opinion, mailed Feb. 11, 2021, in connection with Application No. PCT/US2020/059329.
Kim et al., NAMPT Is an Essential Regulator of RA-Mediated Periodontal Inflammation. J Dent Res. Jun. 2017;96(6):703-711. doi: 10.1177/0022034517690389. Epub Feb. 6, 2017.
Laranjeira et al., Therapeutic target discovery and drug development in cancer stem cells for leukemia and lymphoma: from bench to the clinic. Expert Opin Drug Discov. Nov. 2016;11(11):1071-1080. doi: 10.1080/17460441.2016.1236785. Epub Sep. 25, 2016.
Le et al., Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A. Feb. 2, 2010;107(5):2037-42. doi: 10.1073/pnas.0914433107. Epub Jan. 19, 2010.
Li et al., Epigenetic regulation of NfatC1 transcription and osteoclastogenesis by nicotinamide phosphoribosyl transferase in the pathogenesis of arthritis. Cell Death Discov. Feb. 6, 2019;5:62. doi: 10.1038/s41420-018-0134-6.
Moreno-Vinasco et al., Nicotinamide phosphoribosyltransferase inhibitor is a novel therapeutic candidate in murine models of inflammatory lung injury. Am J Respir Cell Mol Biol. Aug. 2014;51(2):223-8. doi: 10.1165/rcmb.2012-0519OC.
Moschen et al., A key role for Pre-B cell colony-enhancing factor in experimental hepatitis. Hepatology. Aug. 2011;54(2):675-86. doi: 10.1002/hep.24416. Epub Jun. 26, 2011.
Moschen et al., Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. Feb. 1, 2007;178(3):1748-58. doi: 10.4049/jimmunol.178.3.1748.
O'Brien et al., A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. Jan. 4, 2007;445(7123):106-10. doi: 10.1038/nature05372. Epub Nov. 19, 2006.
Romacho et al., Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia. Nov. 2009;52(11):2455-2463. doi: 10.1007/s00125-009-1509-2. Epub Aug. 29, 2009.
Roulsten et al., New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncology. Mol Cell Oncol. Jun. 10, 2015;3(1):e1052180. doi: 10.1080/23723556.2015.1052180.
Saunders et al., A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. Aug. 26, 2015;7(302):302ra136. doi: 10.1126/scitranslmed.aac9459.
Seyfried et al., On the origin of cancer metastasis. Crit Rev Oncog. 2013;18(1-2):43-73. doi: 10.1615/critrevoncog.v18.i1-2.40.
Singh et al., Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors. ACS Chem Biol. Nov. 18, 2016;11(11):3214-3225. doi: 10.1021/acschembio.6b00651. Epub Oct. 17, 2016.
Stromsdorfer et al., NAMPT-Mediated NAD(+) Biosynthesis in Adipocytes Regulates Adipose Tissue Function and Multi-organ Insulin Sensitivity in Mice. Cell Rep. Aug. 16, 2016;16(7):1851-60. doi: 10.1016/j.celrep.2016.07.027. Epub Aug. 4, 2016.
Taniguchi et al., Cancer stem cells in human gastrointestinal cancer. Cancer Sci. Nov. 2016;107(11):1556-1562. doi: 10.1111/cas.13069.
Travelli et al., Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells. Cancer Res. Apr. 15, 2019;79(8):1938-1951. doi: 10.1158/0008-5472.CAN-18-1544. Epub Feb. 18, 2019.
Vallejo et al., Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity. PLoS One. 2011;6(11):e27299. doi: 10.1371/journal.pone.0027299. Epub Nov. 3, 2011.
Wang et al., Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway. Ann Neurol. Feb. 2011;69(2):360-74. doi: 10.1002/ana.22236. Epub Jan. 19, 2011.
Wu et al., Targeting of nicotinamide phosphoribosyltransferase enzymatic activity ameliorates lung damage induced by ischemia/reperfusion in rats. Respir Res. Apr. 24, 2017;18(1):71. doi: 10.1186/s12931-017-0557-2.
Yerxa et al., New Visions in Ophthalmic Drug Development. Drug Discovery World. Dec. 14, 2002. 18 pages. Retrieved from <https://www.ddw-online.com/new-visions-in-ophthalmic-drug-development-1091-200212/>.
Zhang et al., Visfatin is regulated by interleukin-6 and affected by the PPAR-γ pathway in BeWo cells. Mol Med Rep. Jan. 2019;19(1):400-406. doi: 10.3892/mmr.2018.9671. Epub Nov. 20, 2018.
Zheng et al., FK866 attenuates sepsis-induced acute lung injury through c-jun-N-terminal kinase (JNK)-dependent autophagy. Life Sci. Jun. 1, 2020;250:117551. doi: 10.1016/j.lfs.2020.117551. Epub Mar. 13, 2020.

Also Published As

Publication number Publication date
JP2022553865A (ja) 2022-12-26
CN119930509A (zh) 2025-05-06
AU2020378067A1 (en) 2022-05-26
CA3157315A1 (en) 2021-05-14
EP4055008A1 (en) 2022-09-14
WO2021092322A1 (en) 2021-05-14
BR112022008753A2 (pt) 2022-07-19
JP7690470B2 (ja) 2025-06-10
PH12022551081A1 (en) 2024-06-19
KR20220110744A (ko) 2022-08-09
IL292718A (en) 2022-07-01
JP2025143254A (ja) 2025-10-01
CN114929672A (zh) 2022-08-19
CO2022007910A2 (es) 2022-08-19
CN114929672B (zh) 2025-01-21
MX2022005445A (es) 2022-08-10
US20230023124A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
US12612368B2 (en) Cancer treatments targeting cancer stem cells
US10975055B2 (en) Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
US10723753B2 (en) Ras inhibitors and uses thereof
AU2017363307B2 (en) Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
US12415816B2 (en) Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
JP7643874B2 (ja) がん幹細胞を標的化するがん治療
US20240376074A1 (en) Nampt inhibitors and uses thereof
US20220395509A1 (en) A pyrazolopyrimidine derivative as a hck inhibitor for use in therapy, in particular myd88 mutated diseases
EP3334713B1 (en) Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases
US20260125367A1 (en) Cancer treatments targeting cancer stem cells
US20250177391A1 (en) Inhibitors of ddr1 and ddr2 for the treatment of arthritis
HK40120024A (zh) 靶向癌症干细胞的癌症治疗
US20200062776A1 (en) Hedgehog acyltransferase inhibitors and uses thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: REMEDY PLAN, INC., MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BHURRUTH-ALCOR, YUSHMA;CRIMMINS, GREGORY THOMAS;DE JESUS DIAZ, DENNISE ALEXANDRA;AND OTHERS;SIGNING DATES FROM 20210309 TO 20210315;REEL/FRAME:060727/0985

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION COUNTED, NOT YET MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ALLOWED -- NOTICE OF ALLOWANCE NOT YET MAILED

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE